A risk-benefit analysis of factor v Leiden testing to improve pregnancy outcomes: A case study of the capabilities of decision modeling in genomics

Genetics in Medicine

Volumn 15, Issue 5, 2013, Pages 374-381

  Bajaj, Preeti S ^a   Veenstra, David L ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

clinical utility; decision analysis; factor V Leiden; genetic testing; pregnancy

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; HEPARIN;

ADULT; ARTICLE; BLEEDING; COHORT ANALYSIS; FEMALE; GENE MUTATION; GENOMICS; HUMAN; MAJOR CLINICAL STUDY; MATERNAL MORTALITY; PREGNANCY; PREGNANCY OUTCOME; QUALITY ADJUSTED LIFE YEAR; RISK BENEFIT ANALYSIS; SPONTANEOUS ABORTION; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM;

ADULT; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DECISION TREES; FACTOR V; FEMALE; GENETIC TESTING; GENOMICS; HUMANS; MUTATION; PREGNANCY; PREGNANCY OUTCOME; QUALITY-ADJUSTED LIFE YEARS; UNITED STATES;

EID: 84877250322     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2012.139     Document Type: Article

References (39)

1. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes, 3rd edn, Oxford University Press: New York, 2005.
2. Conti R, Veenstra DL, Armstrong K, Lesko LJ, Grosse SD. Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, costeffectiveness, and future research priorities. Med Decis Making 2010;30: 328-340.
3. Veenstra DL, Roth JA, Garrison LP Jr, Ramsey SD, Burke W. A formal riskbenefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practice. Genet Med 2010;12:686-693.
4. Grosse SD, Khoury MJ. What is the clinical utility of genetic testing? Genet Med 2006;8:448-450.
5. Burke W, Pinsky LE, Press NA. Categorizing genetic tests to identify their ethical, legal, and social implications. Am J Med Genet 2001;106:233-240.
6. Burke W, Atkins D, Gwinn M, et al. Genetic test evaluation: information needs of clinicians, policy makers, and the public. Am J Epidemiol 2002;156: 311-318.
7. Clayton EW. Ethical, legal, and social implications of genomic medicine. N Engl J Med 2003;349:562-569.
8. McAllister M, Payne K, Nicholls S, MacLeod R, Donnai D, Davies LM. Improving service evaluation in clinical genetics: identifying effects of genetic diseases on individuals and families. J Genet Couns 2007;16:71-83.
9. Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO; American College of Chest Physicians. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e691S-e736S.
10. Duhl AJ, Paidas MJ, Ural SH, et al.; Pregnancy and Thrombosis Working Group. Antithrombotic therapy and pregnancy: consensus report and recommendations for prevention and treatment of venous thromboembolism and adverse pregnancy outcomes. Am J Obstet Gynecol 2007;197:457.e1-457.21.
11. Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA 1997;277:1305-1307.
12. Rosendaal FR, Reitsma PH. Genetics of venous thrombosis. J Thromb Haemost 2009;7 Suppl 1:301-304.
13. Kujovich JL. Factor V Leiden thrombophilia. Genet Med 2011;13:1-16.
14. Martin JA, Hamilton BE, Ventura SJ, et al. Births: Final Data for 2009. National Vital Statistics Reports; vol 60 no 1. National Center for Health Statistics: Hyattsville, MD, 2011.
15. Arias, E. United States life tables, 2007. National Vital Statistics Reports; vol 59 no 9. National Center for Health Statistics: Hyattsville, MD, 2011.
16. Kovalevsky G, Gracia CR, Berlin JA, Sammel MD, Barnhart KT. Evaluation of the association between hereditary thrombophilias and recurrent pregnancy loss: a meta-analysis. Arch Intern Med 2004;164:558-563.
17. Bradley LA, Palomaki GE, Bienstock J, Varga E, Scott JA. Can Factor V Leiden and prothrombin G20210A testing in women with recurrent pregnancy loss result in improved pregnancy outcomes?: Results from a targeted evidencebased review. Genet Med 2012;14:39-50.
18. Biron-Andreani C, Schved JF, Daures JP. Factor V Leiden mutation and pregnancy-related venous thromboembolism: what is the exact risk? Results from a meta-analysis. Thromb Haemost 2006;96:14-18.
19. Dobesh P. The importance of appropriate prophylaxis for the prevention of venous thromboembolism in at-risk medical patients. Int J Clin Pract 2010;64:1554-1562.
20. Tormene D, Grandone E, De Stefano V, et al. Obstetric complications and pregnancy-related venous thromboembolism: the effect of low-molecularweight heparin on their prevention in carriers of factor V Leiden or prothrombin G20210A mutation. Thromb Haemost 2012;107:477-484.
21. Visser J, Ulander VM, Helmerhorst FM, et al. Thromboprophylaxis for recurrent miscarriage in women with or without thrombophilia. HABENOX: a randomised multicentre trial. Thromb Haemost 2011;105:295-301.
22. Carp H, Dolitzky M, Inbal A. Thromboprophylaxis improves the live birth rate in women with consecutive recurrent miscarriages and hereditary thrombophilia. J Thromb Haemost 2003;1:433-438.
23. Payne MA, Lamb EJ. Use of frozen semen to avoid human immunodeficiency virus type 1 transmission by donor insemination: a cost-effectiveness analysis. Fertil Steril 2004;81:80-92.
24. Tan JM, Macario A, Carvalho B, Druzin ML, El-Sayed YY. Cost-effectiveness of external cephalic version for term breech presentation. BMC Pregnancy Childbirth 2010;10:3.
25. Aledort JE, Hook EW 3rd, Weinstein MC, Goldie SJ. The cost effectiveness of gonorrhea screening in urban emergency departments. Sex Transm Dis 2005;32:425-436.
26. Walleser S, Salkeld G, Donovan B. The cost effectiveness of screening for genital Chlamydia trachomatis infection in Australia. Sex Health 2006;3:225-234.
27. Ottawa Hospital Research Institute; Canadian Institute of Health Research. TIPPS: Thrombophilia in Pregnancy Prophylaxis Study. In: ClinicalTrials.gov [Internet]. National Library of Medicine: Bethesda, MD. http://clinicaltrials.gov/ct2/show/NCT00967382?term=TIPPS&rank=1 NLM Identifier: NCT00967382.
28. Medical University of Vienna. Low Molecular Weight Heparin for Pregnant Women with Thrombophilia: A Prospective, Randomized, Open Trial. In: ClinicalTrials.gov [Internet]. National Library of Medicine: Bethesda, MD. http://clinicaltrials.gov/ct2/show/NCT01019655?term=heparin+AND+preg nancy&rank=4 NLM Identifier: NCT01019655.
29. Grosse SD, Wordsworth S, Payne K. Economic methods for valuing the outcomes of genetic testing: beyond cost-effectiveness analysis. Genet Med 2008;10:648-654.
30. Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ III.Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 2005;143:697-706.
31. James AH, Jamison MG, Brancazio LR, Myers ER. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol 2006;194:1311-1315.
32. Eckman MH, Rosand J, Greenberg SM, Gage BF. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med 2009;150:73-83.
33. Freeman JV, Zhu RP, Owens DK, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 2011;154:1-11.
34. Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 2005;106:401-407.
35. Wilbur K, Lynd LD, Sadatsafavi M. Low-molecular-weight heparin versus unfractionated heparin for prophylaxis of venous thromboembolism in medicine patients-a pharmacoeconomic analysis. Clin Appl Thromb Hemost 2011;17:454-465.
36. Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation 2011;123:2562-2570.
37. O'Brien CL, Gage BF. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. JAMA 2005;293:699-706.
38. Brigham SA, Conlon C, Farquharson RG. A longitudinal study of pregnancy outcome following idiopathic recurrent miscarriage. Hum Reprod 1999;14:2868-2871.
39. Beigi RH, Wiringa AE, Bailey RR, Assi TM, Lee BY. Economic value of seasonal and pandemic influenza vaccination during pregnancy. Clin Infect Dis 2009;49:1784-1792.